2025
Safety of Stimulants Across Patient Populations
Oliva H, Prudente T, Mayerson T, Mignosa M, Oliva I, Potenza M, Jegede O, Angarita G. Safety of Stimulants Across Patient Populations. JAMA Network Open 2025, 8: e259492. PMID: 40343695, PMCID: PMC12065045, DOI: 10.1001/jamanetworkopen.2025.9492.Peer-Reviewed Original ResearchMeSH KeywordsAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsHumansLisdexamfetamine DimesylateMethylphenidateRandomized Controlled Trials as TopicConceptsAttention-deficit/hyperactivity disorderRandomized clinical trialsAdverse eventsStimulant medicationData extractionSafety of stimulationRisk ratioIncreased riskMethodological quality assessmentPreferred Reporting ItemsPatient populationClinical conditionsDiverse patient populationsRisk of biasSafety of stimulant medicationsUnclear risk of biasTreatment of attention-deficit/hyperactivity disorderOverall AEsRandom-effects modelWeb of ScienceBinge eating disorderStimulant use disorderComprehensive literature searchMain OutcomesReporting Items
2024
Treatment for Co-Occurring Stimulant and Opioid Use Disorders
Howell B, Lin L, Coughlin L. Treatment for Co-Occurring Stimulant and Opioid Use Disorders. JAMA Psychiatry 2024, 81: 853-854. PMID: 38985457, DOI: 10.1001/jamapsychiatry.2024.1775.Peer-Reviewed Original ResearchMeSH KeywordsCentral Nervous System StimulantsComorbidityDiagnosis, Dual (Psychiatry)HumansOpioid-Related DisordersSubstance-Related DisordersPreventing overdoses involving stimulants: the POINTS study protocol
Hughto J, Rich J, Kelly P, Vento S, Silcox J, Noh M, Pletta D, Erowid E, Erowid F, Green T. Preventing overdoses involving stimulants: the POINTS study protocol. BMC Public Health 2024, 24: 2325. PMID: 39192313, PMCID: PMC11348517, DOI: 10.1186/s12889-024-19779-x.Peer-Reviewed Original ResearchMeSH KeywordsCentral Nervous System StimulantsDrug OverdoseFentanylHumansMassachusettsRhode IslandRisk FactorsConceptsOpioid-involved overdosesIntervention strategiesPrevent overdoseProtective factorsMultilevel intervention strategiesIntervention development effortsMixed-methods researchMixed-methods findingsHigh-risk communitiesRhode IslandNon-fatal overdoseSocial epidemiologyOverdose preventionCommunity stakeholdersDrug use patternsEpidemiological methodsMulti-pronged approachOverdose crisisBackgroundIn recent yearsStudy protocolCommunity leadersOverdose epidemicDrug checkingIllicit stimulantsRisk factorsAdverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
Zeng L, Perin J, Gross A, Shade D, Lanctôt K, Lerner A, Mintzer J, Brawman‐Mintzer O, Padala P, van Dyck C, Porsteinsson A, Craft S, Levey A, Herrmann N, Rosenberg P. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). International Journal Of Geriatric Psychiatry 2024, 39: e6108. PMID: 38858522, PMCID: PMC11265565, DOI: 10.1002/gps.6108.Peer-Reviewed Original ResearchMeSH KeywordsAccidental FallsAgedAged, 80 and overAlzheimer DiseaseApathyCentral Nervous System StimulantsDouble-Blind MethodFemaleHumansMaleMethylphenidateSleep Initiation and Maintenance DisordersWeight LossConceptsMethylphenidate groupTreating apathyPlacebo-controlled trial of methylphenidateTreatment of apathyAssociated with methylphenidateEffects of methylphenidateTrial of methylphenidateAlzheimer's diseaseFollow-upNo treatment group differencesAdverse effects of methylphenidateDiastolic blood pressureSymptom ChecklistAdverse eventsTreatment group differencesMonitoring weightMethylphenidate useMethylphenidate treatmentMedical comorbiditiesPlacebo groupParticipantsMethylphenidateGroup differencesPlacebo-controlled trialMonthly visitsPatterns of Psychiatric Medication Prescriptions for Veterans in Treatment Courts and Other Specialty Courts
Tsai J, Christian N, Szymkowiak D. Patterns of Psychiatric Medication Prescriptions for Veterans in Treatment Courts and Other Specialty Courts. Journal Of Psychiatric Practice 2024, 30: 119-129. PMID: 38526399, DOI: 10.1097/pra.0000000000000769.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsBenzodiazepinesCentral Nervous System StimulantsDrug PrescriptionsHumansUnited StatesVeteransConceptsCriminal justice-involvedVeterans Treatment CourtsSubstance use disordersPsychiatric medicationsPrescribed psychiatric medicationsTreatment courtsPsychiatric medication prescriptionSpecialty courtsClasses of psychiatric medicationsService-connected disability ratingVA health care servicesBehavioral health issuesJustice-involvedPsychiatric diagnosisUse disorderCourtPsychiatric prescribingPsychiatric prescriptionsClasses of medicationsVeteransService engagementMedication prescriptionsDisordersMedicationHealth care services
2023
Methamphetamine-Associated Catatonia: Case Series and Systematic Review of the Literature from 1943-2020
Slavnic B, Barnett B, McIntire S, Becker R, Saba S, Vellanki K, Honaker L, Weleff J, Carroll B. Methamphetamine-Associated Catatonia: Case Series and Systematic Review of the Literature from 1943-2020. Annals Of Clinical Psychiatry 2023, 35: 167-177. PMID: 37459499, DOI: 10.12788/acp.0116.Peer-Reviewed Original ResearchConceptsAssociated with catatoniaCatatonia Rating ScaleMethamphetamine useGeneral medical conditionsCase seriesBush-Francis Catatonia Rating ScaleSystematic reviewUrine drug screensMedical conditionsRating ScaleCases of catatoniaDSM-5 criteriaShorter hospitalDopamine functionCatatonic patientsCatatoniaDSM-5MethamphetaminePatientsNeural mechanismsSubstance intoxicationDrug screeningHospitalReviewLorazepamASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids
Weimer M, Herring A, Kawasaki S, Meyer M, Kleykamp B, Ramsey K. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids. Journal Of Addiction Medicine 2023, 17: 632-639. PMID: 37934520, DOI: 10.1097/adm.0000000000001202.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnalgesics, OpioidBuprenorphineCentral Nervous System StimulantsHumansOpioid-Related DisordersProspective StudiesConceptsHigh potency synthetic opioidsOpioid use disorderBuprenorphine initiationBuprenorphine treatmentTreatment needsUse disordersClinical considerationsExpert consensusSynthetic opioidsTreatment of OUDProspective researchOpioid agonist treatmentLong-term treatmentDrug supplyPatients' treatment needsOpioid withdrawalBuprenorphine doseOUD treatmentAgonist treatmentDosing frequencyClinical questionsFrontline cliniciansClinical practiceTreatment settingsIndividualized strategiesCost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Lanctôt K, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2023, 35: 664-672. PMID: 37066690, PMCID: PMC10579450, DOI: 10.1017/s1041610223000327.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseApathyCentral Nervous System StimulantsHumansMethylphenidateQuality of LifeConceptsCost-consequence analysisTreatment of apathyFive-level questionnaireTrial 2Quality of lifeBinary logistic regressionPlacebo groupPlacebo treatmentMethylphenidate treatmentSignificant apathyHealth utilityResource utilization costsAlzheimer's diseaseLogistic regressionMethylphenidateTime interactionLevel questionnaireHealthcare systemCost predictorsMeasures analysisPatientsTreatmentDiseaseMonthsUtilization costs
2022
Behaviorally penetrant, anomalous dopamine efflux exposes sex and circuit dependent regulation of dopamine transporters
Stewart A, Mayer F, Gowrishankar R, Davis G, Areal L, Gresch P, Katamish R, Peart R, Stilley S, Spiess K, Rabil M, Diljohn F, Wiggins A, Vaughan R, Hahn M, Blakely R. Behaviorally penetrant, anomalous dopamine efflux exposes sex and circuit dependent regulation of dopamine transporters. Molecular Psychiatry 2022, 27: 4869-4880. PMID: 36117213, DOI: 10.1038/s41380-022-01773-7.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAttention Deficit Disorder with HyperactivityAutism Spectrum DisorderCentral Nervous System StimulantsDopamineDopamine Plasma Membrane Transport ProteinsFemaleMaleMiceSignal TransductionConceptsAnomalous DA effluxDA transporterRegulate DA transporterD2R antagonist sulpirideAttention-deficit/hyperactivity disorderSex-dependent behavioursAutism spectrum disorderSex-dependent alterationsResponse to DAPsychostimulant responsesVentral striatumDA autoreceptorsDopamine effluxDA effluxAntagonist sulpirideDA releaseDA signalingSex-biased effectsAttention-deficit/hyperactivityDopamine transporterNeuropsychiatric disordersCognitive performanceDAT proteinDAT traffickingSpectrum disorderSystemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers
Zakiniaeiz Y, Hoye J, Ryan Petrulli J, LeVasseur B, Stanley G, Gao H, Najafzadeh S, Ropchan J, Nabulsi N, Huang Y, Chen MK, Matuskey D, Barron DS, Kelmendi B, Fulbright RK, Hampson M, Cosgrove KP, Morris ED. Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers. Brain Behavior And Immunity 2022, 106: 262-269. PMID: 36058419, PMCID: PMC10097458, DOI: 10.1016/j.bbi.2022.08.016.Peer-Reviewed Original ResearchMeSH KeywordsCentral Nervous System StimulantsCorpus StriatumDopamineHumansInflammationLipopolysaccharidesMethylphenidatePositron-Emission TomographyRacloprideSmokersConceptsEffects of LPSDopamine elevationTobacco smokersHealthy controlsSystemic inflammationDopamine systemImmune-brain interactionReward-related brain regionsAdministration of placeboAdministration of LPSSmoking statusRepeated-measures ANOVAPathophysiology of addictionDrug dosingPlaceboIndependent cohortSmokersDrug reinforcementEffect size determinationImmune systemRandomized orderBrain regionsLPSMethylphenidatePBO conditionThe practice and embodiment of “goofballs”: A qualitative study exploring the co-injection of methamphetamines and opioids
Ivsins A, Fleming T, Barker A, Mansoor M, Thakarar K, Sue K, McNeil R. The practice and embodiment of “goofballs”: A qualitative study exploring the co-injection of methamphetamines and opioids. International Journal Of Drug Policy 2022, 107: 103791. PMID: 35830749, PMCID: PMC10894463, DOI: 10.1016/j.drugpo.2022.103791.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidCentral Nervous System StimulantsDrug OverdoseHumansMethamphetamineQualitative ResearchConceptsDowntown Eastside neighbourhoodDrug use practicesQualitative studyLittle qualitative researchUse practicesRole of pleasureDepth interviewsQualitative datasetQualitative researchEmbodied experienceDistinct practicesPolysubstance useEffects of opioidsInterviewsPracticeEffects of methamphetamineExperienceSupply interventionsImportant gapOpioidsStimulant useDrugsInitiativesMethamphetamineVancouverPrescription Stimulants and the Risk of Psychosis
Gallagher KE, Funaro MC, Woods SW. Prescription Stimulants and the Risk of Psychosis. Journal Of Clinical Psychopharmacology 2022, 42: 308-314. PMID: 35489031, DOI: 10.1097/jcp.0000000000001552.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmphetamineCase-Control StudiesCentral Nervous System StimulantsChildHumansMethylphenidatePrescriptionsProspective StudiesPsychotic DisordersRetrospective StudiesConceptsObservational studySystematic reviewPsychosis riskCohort studyPrescription stimulantsRetrospective cohort studyProspective cohort studyCase-control studySelf-controlled case seriesInternational Prospective RegisterLongitudinal observational studyMeta-Analyses (PRISMA) guidelinesRisk of psychosisPreferred Reporting ItemsLarge-scale observational studyMPH exposureCase seriesTherapeutic dosesProspective RegisterBias assessmentEligible studiesPsychotic eventsLower riskPsychotic symptomsReporting ItemsCharacterizing stimulant overdose: A qualitative study on perceptions and experiences of “overamping”
Mansoor M, McNeil R, Fleming T, Barker A, Vakharia S, Sue K, Ivsins A. Characterizing stimulant overdose: A qualitative study on perceptions and experiences of “overamping”. International Journal Of Drug Policy 2022, 102: 103592. PMID: 35114520, PMCID: PMC9381030, DOI: 10.1016/j.drugpo.2022.103592.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidCentral Nervous System StimulantsDrug OverdoseHarm ReductionHumansOpiate OverdoseQualitative ResearchConceptsDowntown Eastside neighbourhoodCurrent overdose crisisOverdose crisisNorth America's overdose crisisDepth qualitative interviewsStimulant overdosesHarm reduction campaignsOpioid-related overdose risksQualitative interviewsDominant focusHarm reduction effortsThematic analysisQualitative studyHarm reduction interventionsReduction campaignsRole of stimulantsIndividual experiencesLess attentionReduction effortsCrisisInterviewsExperiencePublic healthOverdose riskReduction interventionsThe effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis
Farhat LC, Flores JM, Behling E, Avila-Quintero VJ, Lombroso A, Cortese S, Polanczyk GV, Bloch MH. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molecular Psychiatry 2022, 27: 1562-1572. PMID: 35027679, DOI: 10.1038/s41380-021-01391-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildHumansMethylphenidateTreatment OutcomeConceptsFixed-dose trialAttention-deficit/hyperactivity disorderDose-limiting adverse eventsChildren/adolescentsAdverse eventsFlexible-dose trialTerms of efficacyClinical practiceHigh dosesFlexible dose designIntolerable adverse eventsHyperactivity disorderIncremental benefitLikelihood of discontinuationADHD symptomsLarge systematic reviewSchool-aged children/adolescentsFlexible titrationPotential long-term effectsSymptom controlTreatment discontinuationClinical outcomesStimulant dosesDaily dosesClinical guidelinesHarm Reduction in Health Care Settings
Chan CA, Canver B, McNeil R, Sue KL. Harm Reduction in Health Care Settings. 2022, 106: 201-217. PMID: 34823731, DOI: 10.1016/j.mcna.2021.09.002.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DrinkingAnalgesics, OpioidBehavior, AddictiveCentral Nervous System StimulantsCounselingDelivery of Health CareDrug OverdoseFentanylHarm ReductionHumansInfection ControlMaleNaloxoneNarcotic AntagonistsNarcoticsOpioid-Related DisordersPre-Exposure ProphylaxisSubstance-Related Disorders
2021
Antidepressants Are the Most Commonly Discontinued Psychotherapeutic Medications in Pregnancy
Germack H, Combellick J, Cooper M, Koller K, McMichael B. Antidepressants Are the Most Commonly Discontinued Psychotherapeutic Medications in Pregnancy. Women's Health Issues 2021, 32: 241-250. PMID: 34840082, DOI: 10.1016/j.whi.2021.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsCentral Nervous System StimulantsFemaleHumansMental DisordersPregnancyConceptsPsychotherapeutic medicationsPerinatal periodPsychiatric illnessAnxiolytics/sedativesMedical Expenditure Panel SurveyUntreated psychiatric illnessMedical Expenditure Panel Survey Household ComponentMedication continuationClinical characteristicsMedication categoriesMood stabilizersAntipsychotic medicationMedicationsPregnancyAntidepressantsHousehold ComponentWomenDemographic characteristicsAntipsychoticsSignificant differencesT-testIllnessFurther researchDiscontinuationAnticonvulsantsMethylphenidate for Apathy in Alzheimer Disease—Why Should We Care?
Fredericks C. Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care? JAMA Neurology 2021, 78: 1311-1313. PMID: 34570178, DOI: 10.1001/jamaneurol.2021.2942.Peer-Reviewed Original ResearchCancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis
Chow R, Bruera E, Sanatani M, Chiu L, Prsic E, Boldt G, Lock M. Cancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis. BMJ Supportive & Palliative Care 2021, 13: 274-280. PMID: 34593386, DOI: 10.1136/bmjspcare-2021-003244.Peer-Reviewed Original ResearchMeSH KeywordsCentral Nervous System StimulantsFatigueHumansMethylphenidateModafinilNeoplasmsNetwork Meta-AnalysisParoxetineConceptsCancer-related fatiguePharmacologic interventionsSystematic reviewCochrane Central RegisterFuture clinical trialsMore safety dataCentral RegisterHead trialsControlled TrialsCommon symptomsFuture trialsClinical trialsSafety dataDirect headMean differenceParoxetineModafinilTrialsInterventionPatientsCancer researchReviewPlaceboEMBASEMEDLINE
2020
Gut dysbiosis associated with the rats' responses in methamphetamine‐induced conditioned place preference
Yang C, Fu X, Hao W, Xiang X, Liu T, Yang B, Zhang X. Gut dysbiosis associated with the rats' responses in methamphetamine‐induced conditioned place preference. Addiction Biology 2020, 26: e12975. PMID: 33094505, DOI: 10.1111/adb.12975.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBehavior, AnimalCentral Nervous System StimulantsConditioning, ClassicalDisease Models, AnimalDysbiosisGastrointestinal MicrobiomeMaleMethamphetamineRatsRats, Sprague-DawleyConceptsMA use disorderGut microbiota compositionGut dysbiosisUse disordersGut microbiotaCPP scoresMicrobiota compositionHigher CPP scoresSusceptible riskRibosomal RNA sequencingCPP trainingRat modelSame doseDrug effectsPlace preferencePotent stimulantDysbiosisRats' responsesImportant modulatorCumulative evidenceRatsLow CPPMethamphetamineDisordersCPPUse of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder
Chawarski MC, Hawk K, Edelman EJ, O'Connor P, Owens P, Martel S, Coupet E, Whiteside L, Tsui JI, Rothman R, Cowan E, Richardson L, Lyons MS, Fiellin DA, D'Onofrio G. Use of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder. Annals Of Emergency Medicine 2020, 76: 782-787. PMID: 32782084, PMCID: PMC8048036, DOI: 10.1016/j.annemergmed.2020.06.046.Peer-Reviewed Original ResearchConceptsUntreated opioid use disorderOpioid use disorderAmphetamine-type stimulant useUse disordersStimulant useAmphetamine-type stimulantsStudy admissionEmergency departmentEmergency department patientsImplementation science studyUrine test resultsFalse discovery rate correctionSubstance use problemsHepatitis CED visitsDepartment patientsReferral protocolsED patientsUrine testsDrug injectionOverdose riskPatientsHealth factorsUnstable housingConcurrent use
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply